TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.

Qin Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.